Concepedia

Tyler S. Beyett

TS

16

Publications

666

Citations

14

H-Index

2017

Active since

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

University of Michigan

University at Buffalo, State University of New York

University of California San Diego

Tyler S. Beyett is an author at Dana-Farber Cancer Institute specializing in pharmacology, medicine, and drug discovery.

ORCID

Top concepts

Publications per year

2017–2024

16

Publications

16

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer

Ciric To, Tyler S. Beyett, Jaebong Jang et al. · Nature Cancer · 2022 · 146 citations · Full text

, , +9

Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors

Tyler S. Beyett, Ciric To, David E. Heppner et al. · Nature Communications · 2022 · 80 citations · Full text

Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib

Emre Tkacik, Kunhua Li, Gonzalo L. González‐Del Pino et al. · Journal of Biological Chemistry · 2023 · 62 citations · Full text

Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer

Ikuko Nakamura, Shinji Kohsaka, Masachika Ikegami et al. · npj Precision Oncology · 2021 · 52 citations · Full text

Carboxylic Acid Derivatives of Amlexanox Display Enhanced Potency toward TBK1 and IKKε and Reveal Mechanisms for Selective Inhibition

Tyler S. Beyett, Xinmin Gan, Shannon M. Reilly et al. · Molecular Pharmacology · 2018 · 50 citations · Full text

Rows per page

1–5 of 16